Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001295|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : September 25, 2018
|First Submitted Date||November 3, 1999|
|First Posted Date||November 4, 1999|
|Last Update Posted Date||September 25, 2018|
|Study Start Date||January 29, 1992|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures
||To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for an active research protocol. [ Time Frame: Open-ended ]|
|Original Primary Outcome Measures||Not Provided|
|Change History||Complete list of historical versions of study NCT00001295 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease|
|Official Title||Continuing Treatment for Children and Adults in the Center for Cancer Research|
|Brief Summary||This protocol is to provide continuing medical/surgical/radio-therapeutic care, treatment and follow-up for NCI patients not currently entered on an active research protocol. No investigational treatments will be administered on this protocol....|
It may be in the interest of the CCR to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol.
To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol.
Subjects who have been previously enrolled on and received treatment according to an approved CCR research protocol. (clinical trial)
It is in the best interest of the subject and the CCR for the subject to continue to receive standard care and follow-up at the NIH.
Medical/surgical/radiotherapeutic care, treatment and follow-up is provided for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on an active research protocol.
No investigational treatments will be administered. This protocol is not be used as a platform to perform pilot studies of off-label uses for standard agents.
|Study Design||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Study Groups/Cohorts||Not Provided|
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Study Completion Date||August 23, 2016|
|Primary Completion Date||Not Provided|
Subjects of any age who have been previously enrolled and treated on an approved CCR research treatment protocol.
It is in the best interests of the subject and the CCR for the subject to continue to receive treatment and follow-up at the NIH.
The subject or guardian signs the informed consent and agrees to the proposed treatment regimen.
Subjects who have not been previously treated on a CCR research treatment protocol.
Subjects who are receiving an investigational therapy.
|Ages||up to 99 Years (Child, Adult, Older Adult)|
|Accepts Healthy Volunteers||No|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||United States|
|Removed Location Countries|
|Other Study ID Numbers||920094
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )|
|Study Sponsor||National Cancer Institute (NCI)|
|PRS Account||National Institutes of Health Clinical Center (CC)|
|Verification Date||August 23, 2016|